EASEE® is an Effective and Well-Tolerated Treatment Option

Two-Year Clinical Data Confirm: High Efficacy and Retention

The multicenter prospective study by Schulze-Bonhage et al. (Epilepsia, 2025) evaluated the efficacy and safety of EASEE® over a 24-month period. The results demonstrate a consistent and clinically relevant therapeutic profile.

Strong Long-Term Efficacy 65.4% responder rate (≥50% seizure reduction) after 2 years

Development of treatment response over time

(Proportion of patients with 50%, 75% and 90% seizure reduction over time)

81% therapy retention: Four out of five patients continued EASEE® therapy through the 2-year follow-up — despite the need for generator replacement in the second year (Note: EASEE® now offers a battery life of at least 3 years)
23% seizure-free in the last month of treatment
No serious adverse events related to procedure or device
Improved Neurocognition
Steady Mood during the study as indexed by NDDI-E score
Positive effect in quality of life (QOLIE-31-P)

Source: Schulze-Bonhage et al., 2025, Two-year outcomes of epicranial Focal Cortex Stimulation in pharmacoresistant focal epilepsy

Sustained Seizure Relief: 68% median seizure reduction

Median Seizure Reduction of EASEE®

vs. published Outcomes from other Neurostimulation Methods

Source: Andreas Schulze-Bonhage, Victoria San Antonio-Arce, Sotirios Kalousios, Eva Martinez-Lizana, Volker Arnd Coenen, Martin Hirsch, 2025, Epicranial focal cortex stimulation for minimally invasive neuromodulation of the epileptogenic region: A review

Superior to DBS/RNS with Fewer Risks: EASEE® delivers strong 24-month efficacy—without the need for craniotomy
No Implantation Effect: Unlike other systems, EASEE® shows no seizure reduction before stimulation begins—confirming that outcomes are driven by therapy, not surgery.
Gentle on the Patient: EASEE® offers a well-tolerated therapy experience without common VNS side effects like hoarseness, coughing, or sleep disturbances.

Source: „Focal Cortex Stimulation with a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Singel-Arm Trials”, Schulze-Bonhage et al. 2023

Patients benefit from a reduction in seizures

In the adjacent image, each bar represents a patient in the EASEE II and PIMIDES I studies. All bars pointing to the left indicate seizure reduction. Bars pointing to the right represent patients who experienced an increase in their seizures in the first six months. Overall, a seizure reduction was achieved in 87.5% of all patients. The four lower bars represent patients who became seizure-free.